Translate Bio prices upsized IPO at $13 midpoint
Summary
Translate Bio, an early-stage biotech developing mRNA therapies for genetic diseases, raised $122 million by offering 9.4 million shares at $13, within the range of $12 to $14 and up from the 7.7 million shares it originally planned to sell. The company planned to list on the Nasdaq under the symbol TBIO, with Citi, Leerink Partners and Evercore ISI as lead managers.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Translate Bio prices upsized IPO at $13 midpoint.”
Original at www.renaissancecapital.com. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/renaissance-translate-bio-ipo-2018-06-28-36f20a1ce2/
, SHA-256 4b147e72cf77eef60a1f65b053e20393a9963156be9e5adebc6225794ddaa9c6.Full text
Translate Bio prices upsized IPO at $13 midpoint Translate Bio, an early-stage biotech developing mRNA therapies for genetic diseases, raised $122 million by offering 9.4 million shares at $13, within the range of $12 to $14. The company had orginally planned to sell 7.7 million shares. Translate Bio plans to list on the Nasdaq under the symbol TBIO . Citi, Leerink Partners and Evercore ISI acted as lead managers on the deal.
File and source
- File
- renaissance-translate-bio-ipo-2018-06-28.html
- Size
- 36,115 bytes
- SHA-256
- 4b147e72cf77eef60a1f65b053e20393a9963156be9e5adebc6225794ddaa9c6
- Original
- www.renaissancecapital.com